AstraZeneca's Trixeo Wins EU Approval As Maintenance Treatment For Asthma

The European Commission approved AstraZeneca's Trixeo Aerosphere as a maintenance asthma treatment for patients aged 12 and older whose disease is inadequately controlled on a medium-dose inhaled corticosteroid and long-acting therapy. The approval expands the addressable European market for Trixeo into adolescent asthma care and provides a positive incremental growth catalyst for AstraZeneca's respiratory franchise.